Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

Clinical trial NCT07082439 · RECRUITING

Trial details

NCT number: NCT07082439
Sponsor: Abramson Cancer Center at Penn Medicine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Adenocarcinoma Metastatic in the Liver

Start date: 2025-09-10
Primary completion: 2027-09-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.